Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BIOGEN INC. Director's Dealing 2011

Apr 21, 2011

30291_dirs_2011-04-21_0c53007b-6310-4e24-b2b9-ecba4095ce5a.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN IDEC INC. (BIIB)
CIK: 0000875045
Period of Report: 2011-04-20

Reporting Person: SCHENK LYNN (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-04-20 Common Stock M 10000 $68.15 Acquired 17980 Direct
2011-04-20 Common Stock S 10000 $85.8086 Disposed 7980 Direct
2011-04-20 Common Stock M 12500 $66.29 Acquired 20480 Direct
2011-04-20 Common Stock M 3125 $46.99 Acquired 23605 Direct
2011-04-20 Common Stock M 5950 $52.22 Acquired 29555 Direct
2011-04-20 Common Stock M 5700 $59.17 Acquired 35255 Direct
2011-04-20 Common Stock S 27275 $85.00 Disposed 7980 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-04-20 Stock Option (Right to Buy) $68.15 M 10000 Disposed 2012-01-01 Common Stock (10000) Direct
2011-04-20 Stock Option (Right to Buy) $66.29 M 12500 Disposed 2015-01-03 Common Stock (12500) Direct
2011-04-20 Employee Stock Option (Right to Buy) $46.99 M 3125 Disposed 2016-05-24 Common Stock (3125) Direct
2011-04-20 Stock Option (Right to Buy) $52.22 M 5950 Disposed 2017-05-30 Common Stock (5950) Direct
2011-04-20 Stock Option (Right to Buy) $59.17 M 5700 Disposed 2018-06-18 Common Stock (5700) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 7600 Indirect

Footnotes

F1: Exercise/sale pursuant to a trading plan intended to comply with Rule 10b5-1 of the Securities Exchange Act of 1934.

F2: This represents the weighted average price for shares sold at a range between $85.78 (low) and $85.86 (high).

F3: Full information regarding the number of shares sold at each separate price will be provided upon request by the SEC staff, the issuer, or a security holder of the issuer.

F4: Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).

F5: Immediately exercisable for all the option shares on grant date of 01/03/2005 subject to Issuer's repurchase rights which lapse on 01/03/2006.

F6: Options will vest in their entirety on 05/25/2007 provided that the Reporting Owner is then a member of the Issuer's Board of Directors.

F7: Options will become 100% exercisable upon completion of one year of service with Biogen Idec Inc.